Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Kennedy calls for banning hundreds of food additives and chemicals. He has called for getting ultra-processed foods out of ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...

With thousands of press releases published each week, it can be difficult to keep up with everything on . To help journalists ...

US regulators believe that Novo Nordisk’s new long-acting, once-a-day insulin, Tresiba, has a notable, but uncertain, cardiovascular risk. An initial assessment, based on a pooled analysis ...

diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by the Trump ...

we used a temporary price dislocation caused by disappointing clinical trial results to purchase shares of Novo Nordisk A/S (NYSE:NVO), a Danish-based leader in diabetes and obesity treatments.

According to Novo Nordisk, over 40% of persons with type 2 diabetes have chronic renal disease, which affects roughly 37 million adults in the United States. Last year, the FDA authorized Wegovy ...

Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes ...